Every round on record, with the sources behind each and the investors on them.
A London-based HealthTech company developing a wearable biosensor platform that detects molecules just beneath the skin
sava.healthLinkedInLondon, UKHealthtechFounded 2019More than 60 members people
5 sources
The supplied source identifies Ascensia as the lead and states the round amount and stage in its title; no other syndicate members or valuation are stated.; not on the page it cites, so not applied: date
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Series B | $36M $68M to date | 2026-10-08 | Ascensia | 4 outlets. #45 in Trending |
5 sources [ VERIFIED · CORRECTED ] read against 1 of 5 sources
The supplied source identifies Ascensia as the lead and states the round amount and stage in its title; no other syndicate members or valuation are stated.; not on the page it cites, so not applied: date | ||||
Sava Technologies is a London-based health-technology company building a wearable biosensor that measures molecules just beneath the skin in real time, starting with glucose monitoring.
Sava is addressing a problem its pages describe as significant: conventional continuous glucose monitors can be invasive, expensive and inaccessible, while only about 1% of people with diabetes use them despite an $11B-plus market. The company’s reported 10-day clinical evidence and $36 million Series B led by Ascensia fund a less invasive, scalable platform that could broaden glucose monitoring and later support other biomarkers.
Checked against 10 sources today
Also named as backers in company research: Balderton Capital, Exor Ventures, European Union, UK Government (through Innovate UK), SOSV, Exceptional Ventures, True, Italian Founders Fund, Athletico Ventures, SOLO Investments, Ascensia Diabetes Care